Literature DB >> 32949174

Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients.

Meng-Lan Wang1, Juan Liao1, Feng Ye2, Ya-Chao Tao1, Dong-Bo Wu1, Min He1, Hong Tang1, En-Qiang Chen1.   

Abstract

Correlations between serum hepatitus B virus (HBV) pregenomic RNA (pgRNA), hepatitus B surface antigen (HBsAg), and hepatitus B core-related antigen (HBcrAg) levels, and influencing factors of serum HBV pgRNA levels in Chinese chronic hepatitis B (CHB) patients are rarely reported. This was a retrospective cohort study consisting of 204 outpatients with CHB. Serum levels of HBV pgRNA, HBsAg, and HBcrAg were quantitative measured in frozen blood samples. The linear regression and multivariate logistic regression analysis were performed to determine associated factors of serum HBV pgRNA levels. In this cohort, the median serum HBV pgRNA level was 4.12 log10 copies/ml and 33.33% (68/204) of them had serum HBV pgRNA under low limit of detection (LLD) (<500 copies/ml); and the percentage of patients with serum HBV pgRNA under LLD in hepatitis B e antigen (HBeAg)-positive patients was significantly lower than that in HBeAg-negative patients (15.75% [23/46] vs. 77.59% [45/58], p < .001). Overall, serum HBV pgRNA strongly correlated with HBcrAg (r = 0.760, p < .001), and moderately correlated with HBV DNA (r = 0.663, p < .001) and HBsAg (r = 0.670, p < .001). As compared with HBsAg and HBV DNA, only HBcrAg showed stable correlation with serum HBV pgRNA both in HBeAg-positive and HBeAg-negative patients. Serum HBV pgRNA level differed between HBeAg-positive and HBeAg-negative patients; and it had better and more stable correlation with serum HBcrAg than serum HBV DNA and HBsAg, irrespective of HBeAg status.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  correlation; distribution; hepatitis B surface antigen; hepatitis B virus core-related antigen; serum HBV pregenomic RNA

Year:  2020        PMID: 32949174     DOI: 10.1002/jmv.26529

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle.

Authors:  Aurélie Schnuriger; Patrick Soussan; Jules Sotty; Pierre Bablon; Bouchra Lekbaby; Jérémy Augustin; Morgane Girier-Dufournier; Lucas Langlois; Céline Dorival; Fabrice Carrat; Stanislas Pol; Hélène Fontaine; Nazim Sarica; Christine Neuveut; Chantal Housset; Dina Kremdsorf
Journal:  Hepatol Int       Date:  2022-08-04       Impact factor: 9.029

2.  Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease.

Authors:  Lisa Pilgram; Lukas Eberwein; Lukas Tometten; Sebastian Dolff; Kai Wille; Felix C Koehler; Melanie Stecher; Siegbert Rieg; Jan T Kielstein; Carolin E M Jakob; Maria Rüthrich; Volker Burst; Fabian Prasser; Stefan Borgmann; Roman-Ulrich Müller; Julia Lanznaster; Nora Isberner
Journal:  Infection       Date:  2021-04-13       Impact factor: 3.553

3.  Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B.

Authors:  Andreas Laras; Margarita Papatheodoridi; Eleni Panopoulou; George V Papatheodoridis; Stephanos J Hadziyannis; Emilia Hadziyannis
Journal:  Virol J       Date:  2022-01-29       Impact factor: 4.099

4.  HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre- and posttreatment: a multicentre observational cohort study.

Authors:  Ling Xu; Xiaodi Li; Lianfeng Lu; Xiaosheng Liu; Xiaojing Song; Yanling Li; Yang Han; Ting Zhu; Wei Cao; Taisheng Li
Journal:  J Viral Hepat       Date:  2022-06-07       Impact factor: 3.517

Review 5.  Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management.

Authors:  Alicia Vachon; Carla Osiowy
Journal:  Viruses       Date:  2021-05-21       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.